Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardima Seeks Suitor For Its Surgical Ablation Catheter Business By June

This article was originally published in The Gray Sheet

Executive Summary

Cardima aims to find an acquirer for the Revelation Tx ablation catheter and all other assets by the end of Q2 to avoid conducting another financing round

You may also be interested in...



CDRH Dispute Resolution Panel Set To Meet For First Time In Years

For the first time in over three years, the ombudsman of FDA's device center has referred a company to the Medical Device Dispute Resolution Panel

CDRH Dispute Resolution Panel Set To Meet For First Time In Years

For the first time in over three years, the ombudsman of FDA's device center has referred a company to the Medical Device Dispute Resolution Panel

Financings In Brief

Adiana: Non-incisional, permanent contraceptive manufacturer will use the proceeds from a $23 mil. Series D financing to complete its pivotal clinical trial, obtain PMA approval and prepare for market launch. The funding was led by Tullis-Dickerson & Co., with OrbiMed Advisors LLC joining as a new investor. Both venture capital firms will be represented on the firm's board of directors, according to Adiana. The company expects to pursue a PMA for the device in early 2006, after completing a 600-patient, 16-site clinical trial. Once approved, Adiana will compete with Conceptus' Essure non-incisional permanent birth-control device(1"The Gray Sheet" Dec. 6, 2004, p. 24)...

Related Content

UsernamePublicRestriction

Register

MT021894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel